The use of resveratrol in the treatment of colon cancer cells has led to a reduction in TGFβ1 and its downstream effector SMAD3, this could be explained by the target of miR-663 on TGFβ1 transcripts [112]. Here, TGFB1 is linked to colonic neoplasm.